Health Care

Dyne Therapeutics insider sales: 200k shares sold at $19.67 under a Rule 10b‑5‑1 plan—neutral market impact, modest dilution, and positive sentiment, keeping growth prospects intact.

Guardant Health’s insider buying signals confidence as quarterly revenue surges 28%, margins strengthen, and a new oncology partnership drives future growth.

QuidelOrtho’s chief legal officer buys 73,435 shares amid a 58% YTD decline, signaling confidence in the LEX Diagnostics deal and potential upside for investors.

Insider buys at Atrium Therapeutics signal confidence in its RNA‑based pipeline and strategic alignment, showing potential upside as Phase II trials and regulatory milestones loom.

Insider buying by the chief medical officer of a psychedelic‑therapeutics company signals strong confidence and market potential, backed by promising Phase 2a data and an accelerating FDA review timeline.

Tilray insider sale analysis: Why David Hopkinson’s April 21 trade matters, its impact on volatility, and what investors should watch for.

Azitra Inc’s insider buying spree signals executive confidence in its dermatology‑engineered protein pipeline, but investors must watch clinical milestones and funding to validate the upside.

Insider buys and sells reveal Hims & Hers’ confidence amid FDA approval and Novo Nordisk settlement—an insider‑driven, risk‑managed strategy poised to grow telehealth, boost reimbursement, and enhance AI‑driven care.

Quantum‑Si’s CFO sell‑to‑cover trade shows disciplined insider activity amid a strategic pivot into renewable‑energy partnerships and value‑based reimbursement, suggesting a stable foundation for biotech investors.

Insider buying fuels confidence in Amarin’s growth, with senior leadership adding ADS and RSUs amid a robust cardiovascular pipeline—what this means for investors.